Search results for "Multivariate analysis"

showing 10 items of 1076 documents

Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological re…

2017

Background Few studies examined the outcome of patients with hepatitis C virus (HCV)-related cirrhosis who developed hepatocellular carcinoma (HCC). The relative weight as determinant of death for cancer vs end-stage liver disease (ESLD) and the benefit of HCV eradication remain undefined. This multicentre, retrospective analysis evaluates overall survival (OS), rate of decompensation and tumour recurrence in compensated HCC patients treated with interferon (IFN) according to HCV status since HCC diagnosis. Methods Two groups of patients with HCV-related cirrhosis and HCC were followed since HCC diagnosis: (i) compensated cirrhotics with prior sustained virological response (SVR) on IFN-bas…

Liver CirrhosisMaleCirrhosisTime FactorsSustained Virologic ResponseHepacivirusKaplan-Meier Estimatemedicine.disease_causeGastroenterologyLiver disease0302 clinical medicineRisk Factorshepatitis C viruLiver Neoplasmsvirus diseasesHepatitis Chepatocellular carcinomainterferonMiddle AgedHepatitis CTreatment OutcomeItaly030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyDrug Therapy CombinationFemalesustained virological responseLiver cancermedicine.medical_specialtyCarcinoma HepatocellularHepatitis C virussurvivalAntiviral Agents03 medical and health sciencesInternal medicineRibavirinmedicinehepatitis C virus; hepatocellular carcinoma; interferon; survival; sustained virological response; HepatologyHumansDecompensationPropensity ScoreAgedProportional Hazards ModelsRetrospective StudiesHepatologybusiness.industryHepatologymedicine.diseasedigestive system diseasesMultivariate AnalysisInterferonsNeoplasm Recurrence LocalbusinessLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study

2017

Background and aims Blood lysosomal acid lipase (LAL) is reduced in non-alcoholic steatohepatitis, which is the major cause of cryptogenic cirrhosis (CC); few data on LAL activity in CC do exist. We investigated LAL activity in a cohort of patients with liver cirrhosis. Methods This is a multicentre cohort study including 274 patients with liver cirrhosis of different aetiology from 19 centres of Internal Medicine, Gastroenterology and Hepatology distributed throughout Italy. Blood LAL activity (nmol/spot/h) was measured with dried blood spot extracts using Lalistat 2. Results Overall, 133 patients had CC, and 141 patients had cirrhosis by other causes (61 viral, 53 alcoholic, 20 alcoholic …

Liver CirrhosisMaleCryptogenic cirrhosis; Liver disease; Lysosomal acid lipase; PathogenesisCirrhosisCryptogenic cirrhosisCryptogenic cirrhosis; Liver disease; Lysosomal acid lipase; Pathogenesis; Cardiology and Cardiovascular MedicineComorbidityPathogenesisLysosonal acid lipase; non-alcoolic fatty liver disease; cirrhosis030204 cardiovascular system & hematologyGastroenterologyLiver disease0302 clinical medicineModel for End-Stage Liver DiseasePathogenesiRisk FactorsPrevalenceProspective cohort studyMultivariate AnalysiSettore MED/12 - GastroenterologiaMiddle AgedItalyCohortLinear Model030211 gastroenterology & hepatologyFemaleCardiology and Cardiovascular MedicineLiver diseaseHumanmedicine.medical_specialtyLiver CirrhosiDown-Regulation03 medical and health sciencesInternal medicineCryptogenic cirrhosis; Liver disease; Lysosomal acid lipase; Pathogenesis; Aged; Biomarkers; Chi-Square Distribution; Comorbidity; Cross-Sectional Studies; Down-Regulation; Dried Blood Spot Testing; Female; Humans; Italy; Linear Models; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Platelet Count; Prevalence; Risk Factors; Sterol EsterasemedicineLysosonal acid lipaseHumansnon-alcoolic fatty liver diseaseAgedCross-Sectional StudieChi-Square Distributionbusiness.industryPlatelet CountcirrhosisRisk FactorBiomarkerCholesterol ester storage diseaseHepatologySterol Esterasemedicine.diseaseCross-Sectional StudiesMultivariate AnalysisLysosomal acid lipaseLinear ModelsDried Blood Spot TestingSteatohepatitisbusinessCryptogenic cirrhosiBiomarkers
researchProduct

Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study

2017

Background & Aims: Metabolic syndrome (MS) and its individual components are associated with the severity and progression of nonalcoholic fatty liver disease (NAFLD). We sought to evaluate the relationship between MS components and the risk of severe hepatic fibrosis in NAFLD patients discriminated by age. Methods: We considered 863 consecutive patients with biopsy-proven NAFLD, who had been fully evaluated for components of MS. Results: Multivariate logistic regression analysis showed that F3-F4 was associated with visceral obesity, IFG/diabetes, and low high-density lipoprotein (HDL) cholesterol, but not triglycerides >150 or arterial hypertension. A significant interaction was found betw…

Liver CirrhosisMaleGastroenterologyBody Mass Index0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver disease10. No inequalityDiabetesAge FactorsMiddle AgedMetabolic syndrome3. Good healthItalyLiver030220 oncology & carcinogenesisObesity Abdominal030211 gastroenterology & hepatologyFemaleWaist CircumferenceLipoproteins HDLAdultmedicine.medical_specialtyDiabetes Complications03 medical and health sciencesDiabetes mellitusInternal medicinemedicineHumansNonalcoholic fatty liver diseaseObesityAgedDiabetes; Metabolic syndrome; Nonalcoholic fatty liver disease; Obesity; HepatologyHepatologybusiness.industrynutritional and metabolic diseasesHepatologymedicine.diseaseObesityMiddle ageCross-Sectional StudiesLogistic ModelsdiabeteMultivariate AnalysisMetabolic syndromeInsulin ResistanceHepatic fibrosisbusiness
researchProduct

Non-invasive assessment of liver steatosis and fibrosis in HIV/HCV- and HCV- infected patients

2013

BACKGROUND: Conflicting data have been reported on the prevalence of liver steatosis, its risk factors and its relationship with fibrosis in patients with human immunodeficiency virus (HIV)/hepatitis C virus (HCV) co-infection or with HCV mono-infection. AIM: The study aims were to assess steatosis prevalence and its risk factors in both HCV groups. We also evaluated whether steatosis was linked with advanced fibrosis. Sixty-eight HIV/HCV co-infected and 69 HCV mono-infected patients were consecutively enrolled. They underwent liver ultrasonography and transient elastography. Bright liver echo-pattern was used to diagnose steatosis; advanced fibrosis was defined as liver stiffness ≥ 9.5 kPa…

Liver CirrhosisMaleHepatic steatosisTransient elastographySpecialties of internal medicineHIV Infectionsmedicine.disease_causeGastroenterologyRisk FactorsFibrosisPrevalenceFIB–4CoinfectionGeneral MedicineHepatitis CMiddle AgedItalyRC581-951Area Under CurveFIB-4Elasticity Imaging TechniquesFemaleLipodystrophyAdultmedicine.medical_specialtyHepatitis C virusLiver fibrosisHepatic steatosiWhite PeopleHIV/HCV co-infectionPredictive Value of TestsInternal medicinemedicineHumansChi-Square DistributionHepatologybusiness.industryLiver fibrosiHepatitis C Chronicmedicine.diseaseImpaired fasting glucoseFatty LiverLogistic ModelsROC CurveMultivariate AnalysisSteatosisMetabolic syndromeTransient elastographybusinessBiomarkersAnnals of Hepatology
researchProduct

HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome.

2015

Aim: To evaluate similarities and differences in HCV-1 subtypes 1a and 1b in the presenting clinical features and the response to peg-interferon and ribavirin (Peg/RIBA).Patients and methods: A total of 1,233 naïve patients with HCV genotype-1 infection, 159 (13 %) with subtype 1a and 1,074 (87 %) with subtype 1b were treated with Peg-IFN/RIBA at 12 Italian centers. Covariates included in the logistic model were age, gender, BMI, serum alanine aminotransferase, serum gamma-glutamiltranspeptidase (γGT), platelets counts, liver fibrosis, the occurrence of type 2 diabetes, baseline viremia, and IL28B genotype.Results: At multivariate analysis, baseline characteristics differentiating patients …

Liver CirrhosisMaleMultivariate analysisclinical featuresChronic HCV liver diseaseType 2 diabetesSex FactorHepacivirusGastroenterologyPolyethylene GlycolPolyethylene Glycolstherapeutic outcomechemistry.chemical_compoundGenotypeAge FactorSettore MED/12 - GastroenterologiaSustained virologic responseAge Factorsvirus diseasesHCV genotype 1 subtypes (1a and 1b)Hepatitis CRecombinant ProteinMiddle AgedRecombinant ProteinsTreatment OutcomeInterferonRNA ViralFemaleHCV subtypeHumanAdultmedicine.medical_specialtyGenotypeLiver CirrhosiAlpha interferonmacromolecular substancesInterferon alpha-2Antiviral AgentsSex FactorsDiabetes mellitusInternal medicineRibavirinmedicineHumansPeg-interferon and ribavirinAntiviral AgentHepaciviruHepatologybusiness.industryRibavirinInterleukinstechnology industry and agricultureInterferon-alphaHepatologyInterleukinHepatitis C Chronicmedicine.diseaseVirologydigestive system diseaseschemistryDiabetes Mellitus Type 2HCV genotypeHCV genotype 1 subtypes (1a and 1b); clinical features; therapeutic outcomeInterferonshepatitis Cbusiness
researchProduct

Serum γ-glutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseases.

2012

Background and Aims: Serum levels of γ-glutamyl-transpeptidase(γ-GT) were associated with liver disease severity and metabolic alterations, which in turn are able to affect hepatic damage. In patients with nonalcoholic fatty liver disease (NAFLD), genotype 1 chronic hepatitis C (G1CHC) and chronic hepatitis B (CHB), we assessed the link between liver fibrosis and γ-GT serum levels, and we evaluated if normal or high γ-GT serum levels affect the association between insulin resistance (IR) and severity of liver fibrosis. Methods: 843 consecutive patients with chronic liver disease (CLD)(193 NAFLD, 481 G1CHC, 169 CHB) were evaluated by liver biopsy (Kleiner and Scheuer scores) and clinical and…

Liver CirrhosisMalePathologylcsh:MedicineNonalcoholic SteatohepatitisChronic liver diseaseBiochemistryGastroenterologyCohort StudiesLiver diseaseEndocrinologyRisk FactorsFibrosisNonalcoholic fatty liver diseaseInsulinGamma-glutamyltransferaselcsh:ScienceSettore MED/12 - GastroenterologiaMultidisciplinarymedicine.diagnostic_testbiologyEnzyme ClassesLiver DiseasesFatty livergamma glutamyl transferase liver fibrosis insulin resistancegamma-GlutamyltransferaseMiddle AgedEnzymesLiver biopsyMedicineFemaleResearch ArticleAdultmedicine.medical_specialtyClinical Research DesignGastroenterology and HepatologySettore MED/08 - Anatomia PatologicaTransferasesInternal medicinemedicineHumansStatistical MethodsBiologyDemographyEndocrine PhysiologyInfectious Hepatitisbusiness.industrylcsh:Rmedicine.diseaseChronic DiseaseMultivariate Analysisbiology.proteinlcsh:QInsulin ResistanceLiver function testsbusinessPLoS ONE
researchProduct

Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cir…

2013

Genetic factors can influence the outcome of antiviral therapy in chronic hepatitis C (HCV). We evaluated the role of interleukin-28B single nucleotide polymorphisms (SNPs) and inosine triphosphatase (ITPA) gene variants in HCV cirrhosis treated with Peg-Interferon and ribavirin. A prospective cohort of 233 patients with compensated cirrhosis received 1-1.5 μg/kg/week of Peg-Interferon alpha-2b plus 1000-1200 mg/day of RBV for 48 weeks. A sustained virologic response (SVR) was achieved in 27% of patients. On multivariate logistic analysis, the absence of oesophageal varices (OR 3.64 CI 95% 1.27-10.44 P = 0.016), infection with genotype 2 or 3 (OR 4.06, CI 95% 1.08-15.26, P = 0.038), C/C all…

Liver CirrhosisMaleSettore MED/07 - Microbiologia E Microbiologia ClinicaAnemia HemolyticGenotypeHepacivirusInterferon alpha-2Esophageal and Gastric VaricesAntiviral AgentsPolymorphism Single NucleotidePolyethylene GlycolsSettore BIO/13 - Biologia ApplicataRibavirinHumanschronic hepatitis C cirrhosis IL-28B inosine triphosphatase sustained virologic responseProspective StudiesPyrophosphatasesGenetic Association StudiesAgedSettore MED/12 - GastroenterologiaDose-Response Relationship DrugInterleukinsInterferon-alphaSequence Analysis DNAHepatitis C ChronicMiddle AgedRecombinant ProteinsLogistic ModelsTreatment OutcomeMultivariate AnalysisDrug Therapy CombinationFemaleInterferonsJournal of viral hepatitis
researchProduct

Prospective evaluation of hepatic steatosis in HIV-infected patients with or without hepatitis C virus co-infection

2012

Background: Limited data are available on hepatic steatosis (HS) in HIV patients who are not infected with hepatitis C virus (HCV). The aims of this study were to assess the prevalence of HS and its risk factors in HIV patients with and without HCV infection, and to evaluate whether HS correlates with advanced liver fibrosis and/or cardiovascular disease risk. Methods: Fifty-seven HIV mono-infected and 61 HIV/HCV co-infected patients were enrolled consecutively. All patients underwent liver ultrasound and transient elastography. The main parameters of liver function, HIV and HCV viral loads, CD4+ cell counts, and data on highly active antiretroviral therapy (HAART) were recorded. Cardiovasc…

Liver CirrhosisMaleSteatosisSettore MED/09 - Medicina InternaLipodystrophyAntiretroviral medicationHIV Infectionsmedicine.disease_causeGastroenterologyHIV/HCV co-infectedLiver diseaseRisk FactorsAntiretroviral Therapy Highly ActivePrevalenceMedicineProspective StudiesSteatosis HIV HIV/HCV co-infected Non-alcoholic fatty liver disease Liver disease Antiretroviral medication Metabolic syndrome LipodystrophyUltrasonographyeducation.field_of_studySettore MED/12 - GastroenterologiaFramingham Risk ScoreCoinfectionvirus diseasesGeneral MedicineMiddle AgedMetabolic syndromeHepatitis CInfectious DiseasesCardiovascular DiseasesFemaleLipodystrophyLiver diseaseViral loadMicrobiology (medical)Adultmedicine.medical_specialtySettore MED/17 - Malattie InfettiveAnti-HIV AgentsHepatitis C virusPopulationInternal medicineHumanseducationbusiness.industryHIVmedicine.diseaseFatty LiverImmunologyMultivariate AnalysisLiver functionbusinessTransient elastographyNon-alcoholic fatty liver disease
researchProduct

Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study

2015

EA Pôle MERS Hors CT hors EJ; International audience; Background & Aims: To compare the management of chronic hepatitis B (CHB) and its evolution over time in currently followed HIV-positive and HIV-negative patients. Methods: A total of 709 consecutive patients with past or present positive HBs antigenemia seen in October 2012 in 19 French participating centres were included. The data were retrospectively collected from the first visit onwards through standardized questionnaires. Results: Chronic hepatitis B was less often assessed in the 299 HIV-positive patients, who were older, more likely to be male, excessive alcohol drinkers and HBe antigen-, HCV- and HDV-positive. They were also fol…

Liver CirrhosisMale[SDE] Environmental SciencesCirrhosis[SDV]Life Sciences [q-bio]HIV InfectionsComorbidityCohort Studies0302 clinical medicineReference ValuesHIV SeropositivityHBV[SDV.BV] Life Sciences [q-bio]/Vegetal Biology030212 general & internal medicineHIV SeronegativityLiver NeoplasmsLamivudinevirus diseasesEntecavirhepatocellular carcinomaMiddle Aged3. Good health[SDV] Life Sciences [q-bio]Treatment OutcomeLamivudineHepatocellular carcinoma[SDE]Environmental SciencesDisease ProgressionFemale030211 gastroenterology & hepatologyFranceCohort studymedicine.drugAdultmedicine.medical_specialtyGuanineAntiviral AgentsRisk AssessmentStatistics Nonparametric03 medical and health sciencesHepatitis B ChronicHIV SeronegativityInternal medicinemedicineHumans[SDV.BV]Life Sciences [q-bio]/Vegetal BiologySurvival analysisRetrospective StudiesHepatitis B Surface AntigensHepatologybusiness.industrycirrhosisHIVmedicine.diseaseSurvival AnalysisComorbiditytenofovirLogistic ModelsMultivariate AnalysisImmunologybusinessentecavir
researchProduct

Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease

2014

BACKGROUND AND AIMS: Variant in glucokinase regulatory protein (GCKR), associated with lipid and glucose traits, has been suggested to affect fatty liver infiltration. We aimed to assess whether GCKR rs780094 C-->T SNP influences the expression of steatosis, lobular inflammation and fibrosis in NAFLD patients, after correction for PNPLA3 genotype. METHODS: In 366 consecutive NAFLD patients (197 from Sicily, and 169 from center/northern Italy), we assessed anthropometric, biochemical and metabolic features; liver biopsy was scored according to Kleiner. PNPLA3 rs738409 C>G and GCKR rs780094 C>T single nucleotide polymorphisms were also assessed. RESULTS: At multivariate logistic regression an…

Liver CirrhosisMalelcsh:MedicineNonalcoholic SteatohepatitisGene FrequencyFibrosisMedicineProspective Studieslcsh:ScienceSicilyliver fibrosisSettore MED/12 - GastroenterologiaMultidisciplinarymedicine.diagnostic_testGlucokinase regulatory proteinbiologyLiver DiseasesFatty liverMiddle Aged3. Good healthItalyLiver biopsyMedicineFemaleResearch ArticleAdultmedicine.medical_specialtyNAFLD GCKRGenotypeGENETICSgene polymorphismSingle-nucleotide polymorphismGastroenterology and HepatologyGLUCKINASESettore MED/08 - Anatomia PatologicaPolymorphism Single NucleotideNAFLDInternal medicineHumansGenetic Predisposition to DiseaseBiologySettore MED/42 - IGIENE GENERALE E APPLICATATriglyceridesPNPLA3Adaptor Proteins Signal TransducingEvolutionary BiologyPopulation Biologybusiness.industrylcsh:RSettore MED/09 - MEDICINA INTERNAComputational BiologyMembrane Proteinsnon-alcoholic fatty liver diseaseLipasePolymorphysmmedicine.diseaseLogistic ModelsEndocrinologyMetabolic DisordersMultivariate AnalysisGenetic Polymorphismbiology.proteinlcsh:QGlucokinase regulatory proteinGene polymorphismSteatosisSteatohepatitisbusinessPopulation GeneticsSteatohepatiti
researchProduct